open access

  • Abstract viewed - 193 times
  • PDF downloaded - 53 times

Abstract

Background: Intravitreal Ozurdex® has been reported to be effective in treating macular oedema. It is more frequently used in resistant diabetic macular oedema cases that do not respond to anti vascular endothelial growth factor treatment. Despite the known risk of implant migration into the anterior chamber in non-intact posterior capsule eyes, the benefit of treatment occasionally outweighs the risk of complications, particularly in cases with good visual potential. The main potential vision-threatening complication involves permanent corneal decompensation.
Case presentation: We are reporting the follow-up and management of Ozurdex implantation in non-intact capsule eyes. The complication of anterior chamber migration if at all occurred, was managed accordingly.
Conclusion: Close follow-up is needed in patients with non-intact posterior lens capsules receiving intravitreal Ozurdex to monitor the risk of anterior chamber migration of the implant.